Time flies fast and we have said “bye” to year 2023 and embraced the new year. By summing up year 2023, Angine team feel proudly that year 2023 was a year with the solid achievements in the fields of on-line event and off-line workshops organization, Angine Global Digital Platform building, as well as the multiple clients consulting and BD partnership serving.
In year 2023, with the topics of "pharmaceutical supply chain & globalization" and " BioPharma Innovation and BD", Angineteam and Reed Sinopharm Exhibitions & Shanghai Sinoexpo/CCCMHPIE jointly organized 4 offline workshops in 4 Chinese cities
During 4 offline workshops, the systematic discussions with more than 500 pharmaceutical colleagues in term of the system construction/international competitiveness improvement of pharmaceutical supply chain , and "international BD capability and transaction mode of innovative drugs" were conducted. The "China Pharmaceutical Supply Chain Conference", initiated and organized by Angine and held in API CHINA for 4 sessions, gradually extended to the perspective of "international supply chain", which also laid the foundation for a more in-depth topic in the th 5th/6th session in 2024. "Biopharma Innovation and BD cooperation" is always a "popular topic" in the pharma industry, and the “Health & Pharma Partner " Innovation and BD Forum has been held online and offline for 4 years by Angine and CPhi China, which has been established as a stage for pharma and biotech BD colleagues in CPHI Shanghai to discuss project cooperation and deal transactions besides the international trade business..
April, 2023. API China Qindao, Shandong Province
June, 2023. CPHI Shanhai
September, 2023. CPHI Guangzhou, Guangdong Province
October, 2023. API China, Nanjing, Jiangsu Province
In year 2023, for building-up a membership based and knowledge shared platform to provide more systematic and in-deepth knowledge/data for cross-boarder life science business as well as market access service, Angine built the first version of the "Angine Global" digital intelligence platform (www.angineglobal.com) based on systematic information and digital marketing approach means..
The "Angine Global" cross-boarder digital intelligence platform is still in the establishing and growing-up stage, but it carries the dream of "internationalization" and "going abroad" of thousands of various enterprises in China as well as multiple global companies which would like to explore the Chinese life science market. The first edition of angineglobal platform systematically launched and sorted out the marketdynamics, regulatory affairs, reimbursement as well as BD partnership opportunities in more than 50 global pharmaceutical markets from four dimensions of "global market, marketaccess, frontier innovation and BD cooperation". Angine team expects to integrate fragmented information from different perspectives in term of life science cross-boarder business into one system, so that users can view overseas business and BD opportunities from a "comprehensive perspective", then equip themself well before stepped into the global market and business.
Angine global's English version has systematically launched and sorted out the market pattern of Chinese generic/innovative drugs, regulatory affairs , reimbursement , leading enterprises in the subdivision fields, and the BD projects with innovation in China, etc. By systematically integrating the corresponding key knowledge in term of China market dynamics, market access regulations as well as the top companies in the subdivision fields, “Angine Global” platform would like to play one of the key platforms in China for foreign companies in the life sciences seeking the China market access as well as BD partnership opportunities.
In year 2023, the activity of short videos and the demand for video courses from Angine’s international colleagues drove Angine’s marketing and content team to build "Angine Global" vedio channels and record BD online courses.
The more than 100 short videos presented by "Angine Global" vedio channel have in-depth and serialized analysis of innovative technology, market regulations, and BD cooperation series from a global perspective. On the other hand, it gives medical and health colleagues a "another perspective" to understand the global life science market in a comprehensive perspectives.
And the BD online courses of “Angine Global" has been built with collecting nearly 30 online and offline conference videos organized by Angine in the past three years, it also includes nearly 60 courses related to “going abroad”recorded by Angine market, access and BD team respectively. The useful knowledge and data in the life science cross-boarder fields with a systematic approach could facilitate the industry counterparts to know more the global markets from various perspectives before firmly step into the global markets.
In year 2023, the founding team of Angine had the overseas trip four times, two trips to Europe, one to Korea, and one to Southeast Asia. Every trip is full of expectations, and Angine team returned home with a potential source of innovative projects and trustful relationships with multinational partners.
April.2023, Switzerland/Austria/Germany
October. 2023, Korea
October.2023, CPhi in Spain
December.2023, Singapore and Indonesia
In year 2023, more than 20 companies and partners signed cooperation agreements with the Angine. Every signing is the testimony of mutual trust and a solemn commitment on both sides. The road of "going abroad" and BD cooperation requires cooperation and deep coordination between the two parties, and trust is extremely important for a long term and mutual benefit business. In year 2024, we look forward to returning this trust with Angine team’sprofessionalism as well as the solid delivery.
In year 2023, Angine's office in Hangzhou received more than 20 foreign friends’visits, and their arrival means their faith in Angine as well as the Angine Global Platform established, also the multiple visits and meetings also accumulated more momentum and solid partnership opportunities in year 2024. "Going global" and "Exploring China" of health and pharma innovation projects need the systematic and professional partnership of overseas partners. Only understanding local "regulations" deeply, the cross-border culture friendly, and communicating in a professional manner to build deep trust will a long-term value be created for both Angine and partners served
At the end of the year 2023, Angine team gathered together and made dumplings to celebrate the new year. The endeavor of "Angine Global" is not easy, because the pathway to “Going abroad” is not smooth, it needs the industry partners to work together and move forward bravely towards the common goal. However, "Angine Global”team" is not alone because of the deep companionship of nearly 10,000 subscribers of “Angine Global”platform, professional empowerment of more than 10 senior global venture partners and hard work by more that 10 Angine full time employee .
The main achievement of “Angine Global”international business and BD service system in year 2023 is the platform foundation building and it is believed that in 2024, Angine teamwill make continuous efforts to present more valuable global business intelligence as well as tailor-made solution by meeting the clients in China as well as other overseas markets’ access as well as BD partnership needs.
For Angine team, we will work based on the following 8 key words to deliver with the professional spirits as well as the capabilities to adapt the changeable external environment. We believe year 2024 will be another fruitful year for Angine team as well as the clients we served if we can work together based on the well-guided market intelligence, big data as well as the trust embodied by the stakeholders in the ecosystem of the cross-boarder life science BD sector.
Let's partner together for the new year and looking forward to more deals done.
About Angine
Angine is a international business development solution provider company dedicated in the pharma, biotech and medical device fields for the global business partnership building. We are working with our overseas' business partner to introduce the clinical and market unmet projects/products to China by leveraging the local expertise and resources as well as “license-out” the innovative pipeline products from China to overseas partners.
With the professional international BD team, the expert consultant group as well as the valuable data room for Chinese markets in the biotech and health care field, Angine is committed to provide the tailor-made solutions for our overseas clients who would like to explore the access to the Chinese market as well as build the win-win partnership with “same-minded”Chinese partner. The solutions are including but not limited to the strategic biz partnership building and right partnership model defining, Chinese market landscape investigation, the regulatory affairs support, the reimbursement policy study, and the ideal incubator & industry park recommendation as well as the capital and talent services supporting.
Angine would like work with you as a strategic partner to co-develop the Chinese healthcare market, to make your ideas, IP become the products by inputting the expertise from both sides and make your products launched in China by the solutions from Angine.
You can write an email to bd@anginebio.com for your ideas and proposals for the Chinese markets. Let our team give you a solution.